Nuo Therapeutics, Inc. reported a significant increase in revenue for the fiscal year ending December 31, 2024, with product revenues reaching approximately $1.365 million, up from $609,000 in 2023. This 124% increase is attributed to growing adoption of the Aurix product among hospital facilities and physician providers, as awareness of its clinical benefits expands. The company also reported a gross profit of approximately $1.062 million, resulting in a gross margin of about 78%. Despite this revenue growth, Nuo Therapeutics continues to face financial challenges, incurring a net loss of approximately $2.3 million for 2024, slightly improved from a net loss of $3.2 million in 2023.
In a strategic development, Nuo Therapeutics entered into a Distribution Agreement with Smith & Nephew PLC on March 31, 2025. Under this agreement, Smith & Nephew will serve as the exclusive distributor of a private label version of the Aurix product in the United States. The agreement includes minimum annual purchase commitments averaging approximately $500,000, and Nuo will receive up to $2.25 million for distribution rights and reimbursement establishment. This partnership is expected to enhance market penetration for the Aurix product, although Nuo anticipates limited sales under this agreement in the immediate future as Smith & Nephew establishes its market presence.
Operationally, Nuo Therapeutics has expanded its sales network, establishing contractual relationships with over 200 third-party representatives, including a multi-state agreement with Pacific Medical, Inc. The company has focused on building relationships with providers treating chronic non-healing wounds, which is critical for increasing product adoption. As of December 31, 2024, Nuo had nine full-time employees, reflecting a lean operational structure as it navigates its recovery and growth strategy.
Looking ahead, Nuo Therapeutics acknowledges the need for substantial additional financing to support its operations and growth initiatives. The company has a history of losses and limited cash resources, raising concerns about its ability to continue as a going concern. Management is actively seeking to secure additional capital to fund its business plan and operational activities. The successful commercialization of the Aurix product will depend on continued acceptance by the medical community and the effectiveness of reimbursement strategies with third-party payors, including Medicare.
About Nuo Therapeutics, Inc.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.